Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4273431 | 0.77 | KDM1A (0.44) | KMT2AMAPTTSHR | |
| SCHEMBL4274373 | 0.77 | MAPT (0.43) | ALDH1A1KMT2ADDB1CRBNNPC1 | |
| SCHEMBL4274464 | 0.75 | CYP17A1 (0.35) | — | |
| SCHEMBL4274482 | 0.73 | DDB1 (0.38) | GSK3BALDH1A1KMT2ADDB1CRBN | |
| SCHEMBL4274297 | 0.69 | GAA (0.41) | ALDH1A1KMT2AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL4273452 | 0.69 | CCNA2 (0.32) | ALDH1A1L3MBTL1 | |
| SCHEMBL4269967 | 0.69 | ADRA1A (0.38) | — | |
| SCHEMBL4269547 | 0.69 | DDB1 (0.47) | GSK3BALDH1A1KMT2ADDB1CRBN | |
| SCHEMBL10737450 | 0.66 | ALDH1A1 (0.51) | GSK3BALDH1A1KMT2ADDB1CRBN | |
| SCHEMBL445499 | 0.65 | MAPT (0.50) | GSK3BALDH1A1KMT2ADDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605183-B2 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO | 2009-10-20 | — | — | US | disclosed |
| US-20080200558-A1 | Inhibitory or blocking agents of molecular generating and/or/ inducing functions | KOYAMA SHOZO | 2008-08-21 | — | — | US | disclosed |
| US-20070066654-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO | 2007-03-22 | — | — | US | disclosed |
| EP-0780122-B1 | DEPRESSANT OF FUNCTIONS DEVELOPED BY MOLECULE | KOYAMA SHOZO (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-20040224926-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6710090-B2 | A CYCLOHEX-1-EN-2-ONE COMPOUND | KOYAMA SHOZO (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20020165206-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | KOYAMA SHOZO (JP) | 2002-11-07 | — | — | US | disclosed |
| US-6346551-B1 | ANTIBACTERIAL, ANTIFUNGAL, ANTIVIRAL, BACTERICIDAL AND/OR STERILIZATION AGENTS, ANTICANCER DRUGS, BLOOD COAGULATION AND FIBRINOLYSIS INHIBITORS AND/OR BLOCKING AGENTS, INHIBITORY AND/OR BLOCKING AGENTS OF ANTIGEN-ANTIBODY REACTIONS | KOYAMA SHOZO (JP) | 2002-02-12 | — | — | US | disclosed |
| EP-0780122-A1 | DEPRESSANT OF FUNCTIONS DEVELOPED BY MOLECULE | Koyama, Shozo (JP) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066654-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | CD47, SERPINB6, CD74 | GSK3B 3744/4885ALDH1A1 1104/4885KMT2A 4262/4885 |
| US-20020165206-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | CD69, TFPI, SERPINE1 | GSK3B 4201/4885ALDH1A1 2177/4885KMT2A 3045/4885 |
| US-20040224926-A1 | Inhibitory or blocking agents of molecular generating and/or inducing functions | CD47, MCL1, CD74 | GSK3B 3194/4885ALDH1A1 595/4885KMT2A 4174/4885 |
| US-20080200558-A1 | Inhibitory or blocking agents of molecular generating and/or/ inducing functions | CD47, MCL1, BAK1 | GSK3B 3633/4885ALDH1A1 1294/4885KMT2A 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.